---

🔬 ESOPHAGEAL CARCINOMA — PART 1

Risk Factors, Types & Clinical Features

Exam-Focused Deep Notes | Surgery | Bailey & Love · Sleisenger · Goldman-Cecil · Harrison

---

📌 OVERVIEW & QUICK STATS (High-Yield Memory Anchors)

Exam fact: Adenocarcinoma surpassed SCC as the most common oesophageal cancer in the USA/UK/West since 1994. SCC still dominates worldwide and in Asia/Africa/Eastern Europe (>90% in those regions).

---

1️⃣ EPIDEMIOLOGY

Global Distribution

• SCC predominates in the "Central Asian Belt" — spanning from the Caspian Sea (Iran) through India, Kazakhstan, to northern China. Also high in parts of eastern Africa (Ethiopia to South Africa).
• Incidence in the belt can be as high as 100/100,000 — making it one of the most cancer-prevalent regions in the world.
• In the USA: SCC rate is 4.93/100,000 men, 2.30/100,000 women; falling by ~3% per year.
• In the USA, 70.8% of oesophageal cancers are now adenocarcinoma (EAC).

Adenocarcinoma Epidemic

• EAC rose 463% in white men and 335% in white women over two decades in the USA.
• EAC is 8× more common in men than women, 5× more common in Caucasians than African Americans.
• Predicted to keep rising until 2030 (projected 8.4–10.1/100,000 person-years).
• Rising trend mirrors the obesity and GERD epidemic in Western countries.

Sex & Age

• Both types: M > F, though the M:F ratio for SCC approaches 1:1 in high-incidence areas like China and Iran.
• Incidence increases sharply after age 50, peaking in 60s–70s.

Prognosis

• Overall 5-year survival remains poor due to late presentation.
• Best outcomes with localised disease — improvements seen in recent years with multimodal therapy.
• Bailey & Love: "Late presentation and early spread are reasons for poor prognosis."

---

2️⃣ TYPES OF OESOPHAGEAL CANCER

A. Squamous Cell Carcinoma (SCC / ESCC)

• Arises from squamous epithelium lining the oesophagus.
• Develops through a sequence: normal epithelium → squamous dysplasia → carcinoma in situ → invasive SCC.
• Most commonly located in the middle third (most common), then upper third.
• Tends to spread longitudinally via submucosal lymphatics — extensive submucosal spread before luminal invasion is classic.
• Gross morphology:
  • Ulcerative (most common — 60%)
  • Fungating / polypoid
  • Infiltrative / stenosing (linitis plastica-like)
  • Superficial spreading

B. Adenocarcinoma (EAC)

• Arises from glandular (columnar) epithelium, almost always in the setting of Barrett's oesophagus (metaplasia from chronic GERD).
• Located predominantly in the lower third and oesophagogastric junction (OGJ).
• Most are mucin-producing with intestinal-type features.
• Pathway: Chronic GERD → Barrett's metaplasia → Low-grade dysplasia → High-grade dysplasia → Invasive adenocarcinoma

Siewert Classification of OGJ Adenocarcinomas (exam favourite):

• Type I: Centre >1 cm above OGJ (true Barrett's/oesophageal adenocarcinoma)
• Type II: Centre within 1 cm above to 2 cm below OGJ (cardia carcinoma — "true junctional")
• Type III: Centre >2 cm below OGJ → staged and treated as gastric cancer

C. Other (Rare) Types — Don't Ignore

• Small cell carcinoma — aggressive, poor prognosis
• Leiomyosarcoma — rare, better prognosis
• Melanoma — primary oesophageal; very rare
• Lymphoma
• Metastatic carcinoma (from breast, lung)
• Carcinosarcoma (spindle cell carcinoma)
• Note: Goldman-Cecil lists: epithelial tumours (SCC, AC, adenoid cystic carcinoma, mucoepidermoid carcinoma) vs. non-epithelial (leiomyosarcoma, GIST, sarcomas, lymphoma, metastatic).

---

3️⃣ RISK FACTORS — DETAILED

🔴 For SQUAMOUS CELL CARCINOMA

The "Big Two" (Synergistic — Most Important in West):

1. Tobacco/Smoking — 3–9× increased risk; includes cigarettes, pipes, cigars, hookah, chewing tobacco, betel quid. Tobacco-specific nitrosamines and polycyclic aromatic hydrocarbons are the main carcinogens.
2. Alcohol — 3–5× increased risk; synergistic with tobacco (combined risk = 10–25× baseline). Risk rises significantly above 140 g/week. Acetaldehyde (first metabolite of ethanol) is a Class I carcinogen.

High-Yield Genetics (Bailey & Love): ~36% of East Asians have deficiency of ALDH2 (aldehyde dehydrogenase 2) — leads to accumulation of carcinogen acetaldehyde after alcohol ingestion. This "flushing response" population has markedly elevated SCC risk.

Dietary & Nutritional Factors (More Important in Developing Countries):

1. Nitrosamines & N-nitroso compounds — found in pickled vegetables, preserved/cured meats, fermented foods. Especially relevant in the Asian esophageal cancer belt.
2. Deficiency of antioxidant vitamins — Vitamins A, B12, C, E, folic acid, niacin, riboflavin.
3. Mineral deficiencies — Zinc, selenium, molybdenum (molybdenum deficiency is classically associated with the Central Asian belt).
4. Hot beverages — drinking very hot tea/mate (thermal injury → chronic irritation → dysplasia).
5. Yerba mate — popular in South America; associated with SCC even after adjusting for other RF.
6. Chewing betel nut — common in South/Southeast Asia.
7. Low socioeconomic status — independent risk factor even after adjusting for tobacco and alcohol.

Preexisting Oesophageal/Systemic Conditions:

1. Achalasia — Stasis of food, chronic fermentation and irritation → SCC (appears 10–20 years after diagnosis of achalasia).
2. Plummer-Vinson (Paterson-Brown-Kelly) syndrome — cervical oesophageal web + iron deficiency anaemia + glossitis → postcricoid / cervical oesophageal SCC in middle-aged women.
3. Tylosis palmaris et plantaris (Howel-Evans syndrome) — autosomal dominant, hyperkeratosis of palms and soles; very high lifetime risk of SCC (>90% by age 65). Gene: RHBDF2 (iRhom2) on chromosome 17q25.
4. Lye/corrosive stricture — SCC develops 20–40 years after corrosive ingestion (lye, acid).
5. Prior head and neck SCC / upper aerodigestive malignancy — field cancerisation effect; SCC of pharynx/larynx/oral cavity shares RF with oesophageal SCC → synchronous or metachronous tumours.
6. Prior mediastinal radiation — risk for both SCC and AC.
7. Celiac disease / nutritional malabsorption
8. Human papillomavirus (HPV) — particularly types 16 and 18; evidence stronger in Asian populations.
9. Fungal toxins — mycotoxins (e.g., fumonisin from Fusarium) implicated in high-incidence areas.

---

🔵 For ADENOCARCINOMA (EAC)

1. Gastro-oesophageal reflux disease (GERD) — strongest risk factor (3–8× increased risk). Acid and bile reflux cause chronic mucosal damage.
2. Barrett's oesophagus — greatest risk factor for EAC (30–125× increased risk vs. general population). Barrett's is intestinal metaplasia of the lower oesophagus replacing normal squamous epithelium.
   • Risk of progression: Low-grade dysplasia → ~0.5%/year; High-grade dysplasia → ~6–7%/year to invasive cancer.
3. Obesity (BMI >30) — independently increases EAC risk 2–5×; increases GERD and raises intra-abdominal pressure. The rising obesity epidemic largely explains the dramatic increase in EAC.
4. Hiatus hernia — predisposes to GERD and Barrett's.
5. White race — 5× more common than in African Americans.
6. Male sex — 8× more common in men.
7. Smoking — modest independent risk (weaker association than in SCC).
8. Bile reflux — bile acids are directly genotoxic.
9. Medications reducing LOS tone — nitrates, anticholinergics, calcium channel blockers (worsen reflux).

Protective Factors for EAC:

• Helicobacter pylori infection (especially CagA+ strains) — protective (reduces gastric acid via gastric atrophy).
• NSAIDs / aspirin — COX-2 inhibition (COX-2 is overexpressed in Barrett's progression to EAC).
• Statin use — some evidence of protective effect.
• Dietary fibre, fresh fruits and vegetables

Bailey & Love summary table confirms: Gastro-oesophageal reflux (+++), Barrett's (++++) → Adenocarcinoma. Alcohol (+++), Smoking (+++) → SCC. Smoking (+) → modest contribution to AC.

---

📊 Bailey & Love Aetiological Factors Table (HIGH-YIELD for MCQs):

---

4️⃣ PATHOGENESIS / MOLECULAR MECHANISMS

SCC Pathogenesis:

• Genetic predisposition → polymorphisms in ALDH2 (alcohol metabolism), DNA repair genes.
• Carcinogens (nitrosamines, acetaldehyde, tobacco components) → DNA adduct formation → p53 mutation (early event in SCC).
• Sequence: chronic irritation → reactive oxygen species → oxidative DNA damage → loss of tumour suppressor genes → clonal expansion.
• Key molecular alterations: p53 (TP53) mutation, CDKN2A (p16) loss, FHIT deletion, EGFR amplification, PIK3CA mutation.

EAC Pathogenesis (Hallmarks of Cancer Applied):

1. Self-sufficiency in growth signals — EGFR, erbB2 (HER2), MET, and IGF-1R amplification drive autonomous proliferation in EAC. TP53 mutations are present in >80% of high-grade dysplasia.
2. Insensitivity to growth inhibitory signals — Loss of tumour suppressor function: p16/CDKN2A gene silencing (via methylation), loss of APC, SMAD4, RUNX3. CDK4 gene amplification removes the cell cycle brake.
3. Resistance to apoptosis — Overexpression of BCL-2 (anti-apoptotic); loss of p53; overexpression of COX-2 (cyclooxygenase-2) — present throughout Barrett's → dysplasia → EAC sequence. COX-2 overexpression correlates with depth of invasion and reduced survival.
4. Unlimited replicative potential — Overexpression of telomerase (hTERT) prevents telomere shortening → immortalisation.
5. Sustained angiogenesis — VEGF overexpression is the most important angiogenic factor; high VEGF = independent poor prognostic factor in ESCC. Fibroblast growth factor receptor 1 (FGFR1) amplification → adverse prognosis in ESCC.
6. Invasion and metastasis — Abnormalities in E-cadherin (CDH1), β-catenin, matrix metalloproteinases (MMPs) → poor differentiation, deeper invasion, nodal metastasis.

---

5️⃣ CLINICAL FEATURES — SYSTEMATIC

🔑 Cardinal Symptom: Progressive Dysphagia (Most Common — ~90%)

• Progressive dysphagia — begins with solids, progresses to soft foods, then liquids, then total obstruction (absolute dysphagia — hallmark of advanced disease).
• Dysphagia to solids typically occurs when luminal diameter is reduced to ≤13 mm (normal: ~20–25 mm).
• Key pattern: "Patient notices difficulty with bread, meat, then soft foods, then liquids".
• Note: The level at which the patient feels food stick is an unreliable indicator of the actual tumour location (Sleisenger & Fordtran).
• Symptoms often ignored initially — patients adapt diet → delayed diagnosis.

🔑 Weight Loss & Cachexia (Very Common)

• Due to decreased oral intake (dysphagia), anorexia, tumour-related catabolism.
• Odynophagia (painful swallowing) — less common than dysphagia; suggests ulcerated lesion.

Symptoms from Local Invasion:

Symptoms from Metastases:

Troisier's sign = palpable left supraclavicular (Virchow's) node — suggests metastatic disease, often from GI malignancy including OGJ adenocarcinoma.

Paraneoplastic Features (Less Common, but Exam Favourites):

• Hypercalcaemia — PTHrP secretion (SCC particularly).
• SIADH — small cell variant.
• Dermatomyositis / acanthosis nigricans — associated with underlying visceral malignancy.

On Examination:

• May be unremarkable in early disease.
• Cachexia, pallor (anaemia from chronic blood loss, especially AC), cervical lymphadenopathy.
• Hepatomegaly in advanced disease.
• Clubbing — rare.
• Supraclavicular / cervical lymph node enlargement — important clinical finding.
• Iron deficiency anaemia — more common in AC than SCC; chronic occult GI bleeding.

---

6️⃣ KEY DIFFERENCES: SCC vs EAC at a Glance (High-Yield Summary)

---

🧠 MEMORY AIDS & EXAM TRICKS

Mnemonic for SCC Risk Factors — "ALPHA WANTS CANCER":

• Alcohol
• Lye corrosive stricture
• Plummer-Vinson syndrome
• Hot beverages / head & neck prior malignancy
• Achalasia
• Weight loss (nutritional deficiencies: vit A, C, E)
• Area of high incidence (Asian belt)
• Nitrosamines (pickled food)
• Tobacco/tylosis
• Cigarette + alcohol = synergistic ×25
• Aldehyde dehydrogenase deficiency (ALDH2)
• Nitroso compounds
• East Asian genetics / environment
• Radiation history

Mnemonic for EAC Risk Factors — "GOBS":

• GERD
• Obesity
• Barrett's oesophagus (the single biggest risk)
• Smoking (minor contribution), Sex (male), Skin colour (white)

Classic Exam Scenario:

A 65-year-old obese white male with a 20-year history of heartburn presents with progressive dysphagia to solids for 3 months and 10 kg weight loss → Oesophageal adenocarcinoma (lower 1/3 / OGJ, Barrett's background).

A 55-year-old male from Kashmir/China, heavy smoker and drinker, presents with dysphagia to solids and hoarseness → Squamous cell carcinoma (middle 1/3 oesophagus).

---

📚 Sources Used

• Bailey and Love's Short Practice of Surgery, 28th Edition (Chapter 66)
• Sleisenger and Fordtran's Gastrointestinal and Liver Disease (Chapter 48)
• Goldman-Cecil Medicine (Chapter 178)
• Current Surgical Therapy, 14th Edition

---

Next parts of this topic to cover:

• Part 2: Pathology (gross & microscopic), Staging (TNM), Diagnosis & Investigations (endoscopy, barium swallow, CT, EUS, PET, staging laparoscopy)
• Part 3: Management (surgery — Ivor Lewis, McKeown, transhiatal; neoadjuvant CRT; palliation; endoscopic treatment; FLOT4, CROSS trial), Prognosis, Prevention & Screening

---

🔪 ESOPHAGEAL CARCINOMA — PART 3

Management, Surgery, Chemoradiotherapy, Palliation & Prognosis

Exam-Focused Deep Notes | Surgery | Bailey & Love · Sabiston · Mulholland · Current Surgical Therapy

---

📌 THE GOLDEN PRINCIPLE OF MANAGEMENT

"Treatment principles depend on disease stage and physiological reserve. All patients must be discussed in a multidisciplinary team (MDT). When distant metastatic disease is identified, palliation is the aim." — Bailey & Love, 28th Ed.

1. Is the tumour resectable? (Stage, local invasion, anatomical suitability)
2. Is the patient fit for surgery? (Physiological reserve, comorbidities, lung function)

---

1️⃣ OVERVIEW: STAGE-DIRECTED TREATMENT ALGORITHM

OESOPHAGEAL CANCER DIAGNOSED
         │
         ├──→ STAGING (CT + EUS + PET ± laparoscopy)
         │
         ├──→ T1a (mucosal) ──────────→ ENDOSCOPIC RESECTION (EMR/ESD ± RFA)
         │
         ├──→ T1b–T2, N0 ────────────→ SURGERY ALONE (selected cases)
         │
         ├──→ T2–T4a, N+ (Resectable locally advanced)
         │         │
         │         ├── AC (lower 1/3, OGJ) → NEOADJUVANT FLOT4 (periop chemo) OR
         │         │                          NEOADJUVANT CROSS (carboplatin/paclitaxel + RT)
         │         │                          → then SURGERY (Ivor Lewis / Transhiatal)
         │         │
         │         └── SCC (mid/upper 1/3) → NEOADJUVANT CROSS (chemoRT)
         │                                    → SURGERY or DEFINITIVE CRT (inoperable)
         │
         ├──→ T4b / Unresectable ────→ DEFINITIVE CHEMORADIOTHERAPY (50–50.4 Gy)
         │                              (curative intent for SCC; AC often palliative)
         │
         └──→ Metastatic (M1) ───────→ PALLIATIVE care:
                                        - Stent insertion (SEMS)
                                        - Palliative chemo (FOLFOX / ECF)
                                        - Radiotherapy (dysphagia relief)
                                        - PEG / feeding jejunostomy
                                        - Best supportive care

---

2️⃣ ENDOSCOPIC TREATMENT (Early Cancer — T1a/T1b)

When Is Endoscopic Treatment Applicable?

• Mucosal cancers (T1a) — Very low risk of nodal metastasis → curative endoscopic resection is the first choice.
• Submucosal cancers (T1b) — SCC: substantial nodal spread risk → surgery usually preferred. AC (Barrett's-related): nodal risk somewhat lower, endoscopic treatment sometimes considered.

A. Endoscopic Mucosal Resection (EMR)

• Technique: Submucosal injection of saline (or glycerol / hyaluronic acid) to lift the lesion → sucked into a cap on endoscope tip → snared and cut by electrocautery ("cap and snare" technique).
• Limitation: Size of cap limits single en-bloc resection → piecemeal resection required for larger lesions → higher incomplete resection and recurrence rates.
• Best for lesions <15–20 mm.

B. Endoscopic Submucosal Dissection (ESD)

• More complex but not limited by lesion size → allows en-bloc resection regardless of size.
• Steps: Mark lesion margins → submucosal injection → mucosal incision along markings → submucosal dissection using endoscopic "knives" → haemostasis.
• Provides full histopathological specimen (unlike ablation).
• Risk: Post-resection stricture if >2/3 circumference removed → mitigated by corticosteroid injection at time of procedure + oral steroids.

C. Radiofrequency Ablation (RFA) — For Barrett's

• Used after EMR/ESD of visible Barrett's cancer → ablates remaining flat Barrett's mucosa.
• Bipolar electrode delivers energy → frictional heating → epithelial destruction.
• In non-acid milieu (with high-dose PPI), epithelium regenerates as squamous mucosa.
• Advantage: Easy to perform; treats wide-field Barrett's.
• Disadvantage: No histopathological specimen.

D. Other Ablative Methods

• Cryotherapy — liquid nitrogen or CO₂ to freeze and destroy tissue.
• Photodynamic therapy (PDT) — photosensitiser (porfimer sodium) + laser light → reactive oxygen species → cell death. Now largely replaced by RFA.
• Argon plasma coagulation (APC)

Exam tip: EMR/ESD preferred over ablation when a histological specimen is needed. RFA is adjunctive for flat Barrett's mucosa after resection of visible dysplasia/cancer.

---

3️⃣ SURGERY — THE CORNERSTONE OF CURATIVE TREATMENT

General Principles of Surgical Resection

• Goal: R0 resection (complete resection with negative microscopic margins) + adequate lymphadenectomy.
• Proximal and distal margins: At least 5 cm of macroscopic clearance required.
• Lymphadenectomy: NCCN guidelines recommend retrieval of ≥15 lymph nodes for adequate staging (Sabiston). More nodes removed = better staging accuracy and possible survival benefit.
• The choice of surgical approach depends on: tumour location, patient factors (lung function, comorbidities), and surgeon experience (surgeon's skills may be more important than approach choice — Mulholland).

---

TYPES OF OESOPHAGECTOMY — The "Big Four"

🔵 1. Ivor Lewis Oesophagectomy (Two-Phase / Two-Incision)

• Phase 1 (Abdominal): Patient supine. Laparotomy/laparoscopy. Inspect for metastatic disease. D2 lymph node dissection (coeliac trunk, hepatic, left gastric artery, superior mesenteric portal vein). Divide left gastric vascular pedicle. Mobilise stomach preserving right gastroepiploic artery (blood supply to conduit). Divide gastrocolic ligament + short gastric vessels. Pyloroplasty or botulinum toxin injection to prevent conduit emptying problems. Create 3–5 cm-wide gastric conduit with linear stapler (from incisura → fundus). Insert feeding jejunostomy tube.
• Phase 2 (Thoracic): Patient repositioned left lateral decubitus. Right lung collapsed (double-lumen ETT or capnothorax). Posterior mediastinal dissection. En-bloc resection of oesophagus with tumour and peri-oesophageal nodes. Gastric conduit pulled up through diaphragmatic hiatus into chest. Intrathoracic oesophagogastric anastomosis (end-to-side or side-to-side; stapled or hand-sewn).

• Best visualisation of entire intrathoracic oesophagus.
• Thoracic anastomosis → lower anastomotic leak rate and stricture rate than cervical anastomosis.
• Excellent mediastinal lymph node dissection.
• No neck incision → lower risk of recurrent laryngeal nerve (RLN) injury.

• Requires one-lung ventilation.
• Thoracic anastomotic leak → mediastinitis (more serious than cervical leak).

---

🟢 2. McKeown Oesophagectomy (Three-Phase / Three-Incision)

• Same thoracic + abdominal steps as Ivor Lewis, but conduit brought up to left neck for cervical anastomosis.
• Cervical anastomosis advantages: Easier to control anastomotic leak (becomes cervical fistula rather than mediastinitis); can achieve wider oesophageal clearance; avoids thoracic anastomosis.
• Cervical anastomosis disadvantages: Higher leak rate (31.7% vs 12.3% intrathoracic in MIE — Sabiston RCT data); higher stricture rate; higher RLN injury rate (4–14%).
• More extensive resection is possible — better for proximal tumours.

---

🟡 3. Transhiatal Oesophagectomy (THE — Orringer Procedure)

• Avoids thoracotomy → less pulmonary morbidity, no need for single-lung ventilation.
• Ideal for poor lung function patients.
• Major limitation: Blind mediastinal dissection → inadequate lymph node dissection of mid and upper mediastinum → less accurate staging, potentially inferior oncological clearance.
• Risk of injury to thoracic structures (aorta, azygos vein, trachea) during blind dissection.
• For mid and upper oesophageal SCC, transhiatal approach may be dangerous (proximity to great vessels, trachea).

---

🔴 4. Left Thoracoabdominal Approach

---

SUMMARY TABLE: Choosing the Right Approach

---

Gastric Conduit — Reconstruction

• Gastric tube (conduit) is the preferred reconstructive option — uses the right gastroepiploic artery as blood supply.
• Width: 3–5 cm (narrower = better emptying, less redundancy).
• If stomach unavailable (prior gastrectomy, devascularisation): colon interposition or jejunal free flap/pedicled loop.
• Preoperative gastric conditioning: In high-risk patients, selective embolisation of left gastric, right gastric, and splenic arteries before surgery to promote collateral blood supply to right gastroepiploic territory → reduces anastomotic leak and conduit ischaemia (Sabiston).

Pyloroplasty / Pyloric Drainage

• Vagotomy occurs during oesophagectomy → gastroparesis risk → gastric conduit empties poorly.
• Options to prevent conduit dysfunction:
  • Pyloroplasty (Heineke-Mikulicz widening of pylorus)
  • Pyloromyotomy
  • Botulinum toxin injection into pylorus (endoscopic)
  • Some centres omit it in all patients — controversial.

---

4️⃣ MINIMALLY INVASIVE OESOPHAGECTOMY (MIE)

• Rapidly replacing open surgery worldwide: 38% in 2010 → 57% in 2015 (Sabiston/USA data).
• Uses video-assisted thoracoscopy (VATS) + laparoscopy ± robotic assistance.
• Steep learning curve and higher technical complexity.

• ↓ pulmonary complications (pneumonia, ARDS)
• ↓ major complications overall
• Shorter hospital stay
• Faster functional recovery
• Similar oncological outcomes (survival) to open surgery

Exam key point: MIE is now the more common approach globally; equally effective oncologically, less morbidity.

---

5️⃣ LYMPHADENECTOMY — EXTENT AND FIELDS

• SCC: At least total 2-field dissection (Japanese data shows significant nodal spread around bilateral RLN chains). Three-field for upper thoracic SCC.
• EAC: Infracarinal 2-field (+ D2 abdominal dissection).
• OGJ tumours: Controversial — either oesophagectomy + 2-field OR extended total gastrectomy with lower oesophageal resection.

Bailey & Love: "Transhiatal oesophagectomy does not allow adequate mediastinal nodal dissection — the mid and upper thoracic mobilisation is mostly a 'blind' procedure."

---

6️⃣ NEOADJUVANT THERAPY — THE LANDMARK TRIALS (EXAM ESSENTIAL)

Why Neoadjuvant?

• Downstaging → increases R0 resection rate.
• Treats micrometastatic disease early.
• Biological response can be assessed — pathological complete response (pCR) is a strong prognostic marker.
• Challenge: ~50% of patients cannot complete postoperative chemotherapy → pushed toward total neoadjuvant approaches.

---

🏆 THE CROSS TRIAL (Most Important — Learn This Cold)

Memory trick: CROSS = Carboplatin + Paclitaxel + Radiation Oesophageal Surgery Study.

---

🏆 FLOT4 TRIAL (Most Important for Adenocarcinoma)

---

🏆 MAGIC TRIAL (Historical — Still Examined)

---

🏆 MRC OEO2 TRIAL (UK)

---

Definitive Chemoradiotherapy (No Surgery)

• Indication: Unresectable tumours (T4b), cervical oesophageal SCC (surgery technically morbid), patients unfit for surgery, patient refusal.
• Dose: 50–50.4 Gy with concurrent chemotherapy (cisplatin + 5-FU, or carboplatin + paclitaxel).
• SCC responds better to definitive CRT than AC.
• For cervical oesophageal SCC: definitive CRT is preferred over surgery (given the morbidity of pharyngolaryngo-oesophagectomy).
• INT-0123 & ARTDECO trials: Higher radiation doses (>50 Gy) did NOT improve locoregional control → standard dose remains 50 Gy.

---

7️⃣ ADJUVANT THERAPY

Adjuvant Chemotherapy / CRT

• Less commonly used than neoadjuvant.
• FLOT4: Postoperative FLOT × 4 cycles after 4 cycles preop.
• CHECKMATE 577 Trial (2021): Adjuvant nivolumab (anti-PD-1 immunotherapy) given after neoadjuvant CRT + surgery in patients who did NOT achieve pCR → doubled disease-free survival (22.4 months vs 11 months). Now standard of care in this setting.

---

Targeted Therapy & Immunotherapy

PD-L1 CPS (combined positive score): Used to select patients for immunotherapy; CPS ≥10 has highest benefit.

---

8️⃣ PALLIATIVE TREATMENT (Unresectable / Metastatic)

A. Self-Expanding Metallic Stent (SEMS) — First-Line Palliation for Dysphagia

• Immediately relieves dysphagia.
• Inserted endoscopically under fluoroscopic guidance.
• Covered stents preferred for fistulas (seals the oesophago-tracheal/bronchial fistula).
• Complications: Stent migration, tumour ingrowth (with uncovered stents), bleeding, perforation, reflux (lower oesophageal stents crossing OGJ).

B. Palliative Radiotherapy

• 30–35 Gy (conventional modest dose) effective for mitigating malignant dysphagia.
• External beam RT (EBRT).
• Brachytherapy (intraluminal radiation) — delivers high-dose radiation locally; good for dysphagia palliation; better long-term dysphagia control than stent in some studies.

C. Palliative Chemotherapy

• FOLFOX (folinic acid + 5-FU + oxaliplatin)
• ECF/ECX (epirubicin + cisplatin + 5-FU/capecitabine)
• Immunotherapy (pembrolizumab / nivolumab ± chemotherapy)
• Modest survival benefit; improves quality of life.

D. Nutritional Support

• Percutaneous endoscopic gastrostomy (PEG) — for prolonged nutritional support (but caution if patient may undergo oesophagectomy, as PEG compromises gastric conduit).
• Nasojejunal tube — short-term.
• Feeding jejunostomy — placed surgically at time of oesophagectomy or as standalone procedure.
• Total parenteral nutrition (TPN) — reserved for those with no enteral access.

E. Laser Therapy / Argon Plasma Coagulation (APC)

• Endoscopic tumour ablation for dysphagia palliation.
• Nd:YAG laser vaporises tumour tissue.
• Requires repeat sessions; mainly for non-circumferential exophytic tumours.

F. Photodynamic Therapy (PDT)

• Photosensitiser + laser → tumour necrosis.
• Used for palliation of malignant dysphagia when stenting not feasible.

G. Oesophago-Airway Fistula Management

• Covered SEMS is treatment of choice.
• Patients often require feeding jejunostomy as nothing can be swallowed safely.

---

9️⃣ POST-OPERATIVE COMPLICATIONS OF OESOPHAGECTOMY

RLN injury mnemonic: "Right thoracic = low risk (1–4%); cervical anastomosis = higher risk (4–14%)."

---

🔟 PROGNOSIS

Factors Affecting Prognosis:

• Stage at diagnosis — most important determinant.
  • T1N0M0 → 5-year survival >80% after endoscopic/surgical resection.
  • T2N0M0 → 5-year survival ~50–60%.
  • T3N1 → 5-year survival ~20–30% (with multimodal therapy).
  • M1 (metastatic) → median survival <12 months; 5-year survival <5%.
• R0 resection (clear margins) — essential for curative intent.
• Pathological complete response (pCR) after neoadjuvant CRT → best survival outcomes.
• Number of positive lymph nodes — independent predictor.
• Tumour type: SCC responds better to CRT; AC generally worse prognosis overall.
• Comorbidities and physiological reserve.
• Surgeon and centre volume — high-volume centres have significantly lower operative mortality.

Operative Mortality of Oesophagectomy:

• Has decreased over decades but remains 3–5% in high-volume centres.
• Can be >10% in low-volume centres.
• Hospital volume effect is one of the strongest predictors of surgical mortality for oesophagectomy.

---

🔑 PREVENTION & SCREENING

Primary Prevention:

• Stop smoking and alcohol — most impactful for SCC.
• Weight reduction / obesity management — reduces EAC risk.
• Treatment of GERD — long-term PPI therapy; antireflux surgery (Nissen fundoplication) in selected patients.
• Diet: Increase fresh fruits, vegetables, antioxidant vitamins; reduce pickled/preserved foods.
• H. pylori eradication — may be protective against EAC (reduces gastric acid → less reflux).

Secondary Prevention / Surveillance:

• Barrett's oesophagus surveillance:
  • No dysplasia → endoscopy every 3–5 years.
  • Low-grade dysplasia → every 6–12 months or RFA.
  • High-grade dysplasia → RFA or EMR/ESD (surveillance alone no longer acceptable).
• Post-GERD treatment monitoring → patients with confirmed Barrett's enter endoscopic surveillance programs.
• Screening for SCC: Countries with high incidence (China, Iran) use chromoendoscopy with Lugol's iodine for mass/targeted screening — abnormal (dysplastic/cancerous) mucosa remains unstained while normal squamous mucosa stains brown.

---

🧠 HIGH-YIELD EXAM MEMORY POINTS

The "CROSS" Regimen — Learn the numbers:

• Carboplatin + Paclitaxel (weekly ×5) + 41.4 Gy RT → surgery
• pCR: 49% SCC, 23% AC
• Median OS doubled (49.4 vs 24 months)

The "FLOT4" Regimen — For EAC:

• Docetaxel + Oxaliplatin + Leucovorin + 5-FU (4+4 cycles)
• Median OS 50 vs 35 months over ECF (MAGIC regimen)

The Three "S" Rules for Stage-Based Surgery:

• Stage I (T1a): Scope it (endoscopic)
• Stage I–II (T1b–T2): Surgery alone (selected)
• Stage II–III (T2–T4a, N+): Sandwich (neoadjuvant CRT or chemo → surgery → adjuvant)

Palliative Dysphagia — "STAB":

• Stent (SEMS) — first line
• Tubes (PEG/jejunostomy) — nutrition
• Ablation/APC — endoscopic tumour debulking
• Brachytherapy/RT — radiation palliation

Surgical Approach Selection — "IVM":

• Ivor Lewis = mid/distal (most common worldwide)
• V (Three = McKeown) = upper/cervical
• M = Minimal access = transhiatal (no chest, poor lungs)

---

🏥 CLASSIC EXAM SCENARIOS

Scenario 1: 60-year-old with resectable T3N1 lower oesophageal adenocarcinoma, fit for surgery. What is the treatment? → Neoadjuvant FLOT4 chemotherapy (4 cycles) → Ivor Lewis oesophagectomy + D2 lymphadenectomy → 4 cycles postop FLOT4. If no pCR → adjuvant nivolumab (CHECKMATE 577).

Scenario 2: 55-year-old with T3N1 mid-oesophageal SCC. What treatment? → Neoadjuvant CROSS protocol (carboplatin + paclitaxel + 41.4 Gy) → McKeown or Ivor Lewis oesophagectomy.

Scenario 3: 70-year-old with metastatic oesophageal AC (liver metastases), poor performance status. What is management? → Palliative SEMS for dysphagia + palliative chemotherapy (FOLFOX or ECF ± pembrolizumab if PD-L1 CPS ≥10) + nutritional support + MDT/palliative care team.

Scenario 4: T1a cancer in Barrett's oesophagus, no evidence of nodal disease on EUS. What treatment? → EMR or ESD (en-bloc resection) + RFA of remaining Barrett's mucosa. Surgery not required.

Scenario 5: Patient with cervical oesophageal SCC, technically resectable but surgery would require laryngectomy. What treatment? → Definitive chemoradiotherapy (50–50.4 Gy + cisplatin/5-FU) — organ preservation strategy preferred for cervical oesophageal SCC.

---

📚 Sources

• Bailey and Love's Short Practice of Surgery, 28th Edition (Chapter 66)
• Sabiston Textbook of Surgery, Latest Edition (Chapter 84)
• Mulholland and Greenfield's Surgery, 7th Edition (Chapter 43)
• Current Surgical Therapy, 14th Edition
• Sleisenger and Fordtran's Gastrointestinal and Liver Disease (Chapter 48)
• Goldman-Cecil Medicine (Chapter 178)

---

Want Part 2 (Pathology, TNM Staging & Investigations — Barium swallow, Endoscopy, CT, EUS, PET) next? Or shall we move on to the next surgical topic?